Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Multiple Myeloma: A Journey From Pharaoh's Times to 2024

Houston Methodist

S. Ganguly

ASH 2024 Summary: Transplant in Myeloma - Key Factors in Decision-Ma…

2024 ASH Annual Meeting Insights Hub

A. Perrot

Advances in Multiple Myeloma 2024: From Bench to Bedside

Dana-Farber Cancer Institute

K. Anderson

HSCT in 2024: What Every Hematologist Needs to Know

Indy Hematology Review

R. Childs

Managing Newly Diagnosed MM in 2024

Indy Hematology Review

S. Usmani

ASH 2024 Insights: Secondary Heme Malignancies in Myeloma Post-CAR-T…

2024 ASH Annual Meeting Insights Hub

J. Waldschmidt

ASH 2024 Insights: Optimizing Therapy Duration for Transplant-Inelig…

2024 ASH Annual Meeting Insights Hub

C. Pawlyn

D-VRd With D-R Maintenance in Transplant-Eligible NDMM: PERSEUS Cyto…

Meletios Dimopoulos

The Future of Multiple Myeloma: SCT, CAR-T, and BiTE Therapy

University of Colorado Division of Hematology

K. Sidor

Hematologic Malignancies Update: Treatment Strategies for AML, DLBCL…

Total Health

M. Rotta

2024 Updates on Multiple Myeloma Treatment

University of Colorado Division of Hematology

D. Sherbenou

CAR-T vs. Bispecific Antibodies in R/R MM: Insights and Future Direc…

Rush University Medical Center

A. Suvannasankha

Updates on the Management of 1L Multiple Myeloma

UNC Lineberger Comprehensive Cancer Center

S. Rubinstein

Key Myeloma & MGUS Updates From ASH

Memorial Sloan Kettering Cancer Center

S. Mailankody

ASH 2024 Insights: Ide-Cel in NDMM With Inadequate Response to 1L AS…

2024 ASH Annual Meeting Insights Hub

B. Paul

Updates on the Management of Later Relapses of Multiple Myeloma

UNC Lineberger Comprehensive Cancer Center

S. Rubinstein

Multiple Myeloma: Clinical Challenges for the Community Clinician

Winship Cancer Institute - Emory University

N. Joseph

ASH 2024 Insights: VRD Consolidation and Len Maintenance in MM - Lon…

2024 ASH Annual Meeting Insights Hub

P. Sonneveld

PERSEUS Study Primary Results: Daratumumab + VRd vs. VRd Alone in Pa…

Meletios Dimopoulos